Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Apr 6:12:2023-1-5.
doi: 10.7573/dic.2023-1-5. eCollection 2023.

Silymarin in the management of liver enzyme activity in steatohepatitis: a case report

Aldo Torre  1
Affiliations
Case Reports

Silymarin in the management of liver enzyme activity in steatohepatitis: a case report

Aldo Torre. Drugs Context. .

Abstract

Metabolic-associated fatty liver disease (MAFLD) is the main condition of altered liver enzymes worldwide. With a constant increase in liver hospitalizations, MAFLD is the second cause of cirrhosis and soon will be the first cause of liver transplantation. Early recognition of MAFLD and a personalized approach are essential to its treatment. This case study presents personalized management of a patient with MAFLD with advanced fibrosis and severe steatosis. The impact of silymarin use, concomitant treatment with diet, exercise, insulin sensitizers and antifibrotic agents, was evaluated. This article is part of the Current clinical use of silymarin in the treatment of toxic liver diseases: a case series Special Issue: https://www.drugsincontext.com/special_issues/current-clinical-use-of-silymarin-in-the-treatment-of-toxic-liver-diseases-a-case-series.

Keywords: abnormal liver functions; advanced fibrosis; case report; metabolic-associated fatty liver disease; non-alcoholic steatohepatitis; silymarin; treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the author is available for download at: https://www.drugsincontext.com/wp-content/uploads/2023/03/dic.2023-1-5-COI.pdf

References

    1. Gallego-Durán R, Albillos A, Ampuero J, et al. Metabolic-associated fatty liver disease: from simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH), Gastroenterol Hepatol; 2022; pp. 724–734. - DOI - PubMed
    1. Navarro VJ, Belle SH, D’Amato M, et al. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial. PLoS One. 2019;14(9):e0221683. doi: 10.1371/journal.pone.0221683. - DOI - PMC - PubMed
    1. Kalopitas G, Antza C, Doundoulakis I, et al. Impact of silymarin in individuals with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutrition. 2021;83:111092. doi: 10.1016/j.nut.2020.111092. - DOI - PubMed
    1. Gillessen A, Schmidt HH. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020;37(4):1279–1301. doi: 10.1007/s12325-020-01251-y. - DOI - PMC - PubMed
    1. Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329–338. doi: 10.14218/JCTH.2021.00178. - DOI - PMC - PubMed

Publication types